Healthpeak Properties
DOC
$20.30
-0.34%
Healthpeak Properties, Inc. is a real estate investment trust that owns and operates a diversified healthcare real estate portfolio of approximately 700 in-place properties, concentrated primarily in medical office buildings and life science assets, with additional exposure to senior housing, hospital, and skilled nursing/post-acute care facilities. As one of the larger dedicated healthcare REITs, Healthpeak occupies a distinct position as a scaled owner-operator with a three-pillar platform spanning outpatient medical, lab, and senior housing, rather than a pure-play niche landlord. The current investor narrative centers on the durability of the life science leasing recovery, the trajectory of medical office occupancy, and the company's ability to grow same-store net operating income against a still-elevated interest rate backdrop that pressures both financing costs and capitalization rates. Recent quarterly results showed revenue growth of roughly 7% year over year, but the stock has lagged the broader market over the past three and twelve months, leaving investors debating whether the discounted valuation and 7.6% dividend yield represent a compelling income opportunity or a value trap tied to structural life science demand concerns.…
DOC
Healthpeak Properties
$20.30
Investment Opinion: Should I buy DOC Today?
The synthesized recommendation is Hold, with a thesis that Healthpeak offers an attractive 7.59% dividend yield and deep asset-value discount, but near-term earnings visibility is poor and analyst conviction is weakening. The consensus recommendation is Buy with a mean of 2.41, and the average target price of $23.05 implies 13.6% upside, which is moderate for a REIT and does not compensate for the elevated execution risk. The recent downgrades by Barclays and Morgan Stanley to Equal Weight suggest the market is not yet convinced of a fundamental inflection.
Supporting evidence includes a price-to-book of 1.49x, which is below the 2.03x seen in Q4 2022 and near the 1.25x trough of Q1 2024, suggesting the stock is not expensive on asset value. Revenue grew 7.12% year over year in Q1 2026 to $752.95 million, and EBITDA improved to $576.94 million from $395.53 million a year earlier, showing operating leverage. Free cash flow of $1.182 billion on a trailing basis covers the dividend at 1.12x, supporting the 7.59% yield. However, the trailing PE of 160.80x and forward PE of 145.00x are extreme, and the 11.90% GAAP payout ratio raises questions about earnings quality. Without explicit industry average multiples, a precise peer comparison is not possible, but the EV/EBITDA of 14.31x is broadly in line with diversified healthcare REITs.
The biggest risks that could invalidate the thesis are a dividend cut if free cash flow coverage deteriorates below 1.0x, a sustained breakdown in life science leasing that pushes occupancy lower, and further analyst downgrades that compress the multiple. This Hold would upgrade to Buy if price-to-book compresses below 1.25x or if same-store NOI growth accelerates above 3%, and it would downgrade to Sell if revenue growth decelerates below 5% or if the dividend coverage ratio falls below 1.0x. Relative to its own history, DOC is undervalued on book and sales metrics, but the persistent earnings weakness and structural concerns justify a cautious stance. The stock is fairly valued to slightly undervalued for income-focused investors, but not a compelling growth or total-return opportunity at current levels.
Sign up to view all
DOC 12-Month Price Forecast
Healthpeak presents a balanced risk/reward with a neutral stance, as the attractive dividend and discounted asset valuation are offset by weak GAAP earnings and structural concerns in life science and medical office. The 7.59% yield is well covered by free cash flow, but the 160.80x trailing PE and 145.00x forward PE highlight how little accounting profit the business retains. Analyst sentiment is modestly positive with a $23.05 average target, but the recent downgrades and wide target range signal fading conviction. The base case of $21-$24 (55% probability) assumes stable leasing and no rate shocks, while the bear case of $15.70-$17.00 (20% probability) reflects a dividend cut or cap-rate spike. I would upgrade to bullish if life science leasing inflects and occupancy rises above 90%, and downgrade to bearish if dividend coverage falls below 1.0x or revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $23.05 and implied upside of +13.6% versus the current price.
Average Target
$23.05
0 analysts
Implied Upside
+13.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $29
Analyst target range
Coverage is robust with 19 analysts, and the consensus recommendation is Buy with a recommendation mean of 2.41, though the distribution skews toward the cautious end of bullish given the prevalence of Neutral and Equal Weight ratings. The average target price of $23.05 implies roughly 13.6% upside from the current price of $20.30, a moderate but not overwhelming expected return that is consistent with a mature, income-oriented REIT rather than a high-growth compounder. The consensus leans modestly bullish, but the 2.41 mean (where 1.0 is Strong Buy and 3.0 is Hold) indicates the average analyst is closer to a Hold than a Strong Buy, reflecting tempered enthusiasm. The target range is wide, spanning from a low of $17.00 to a high of $29.00, a $12.00 spread that equals roughly 59% of the current share price and signals meaningful disagreement about the company's trajectory. The high target of $29.00 implies roughly 43% upside and would require multiple expansion alongside accelerating life science leasing and medical office occupancy, effectively pricing in a full normalization of healthcare real estate demand. The low target of $17.00 implies about 16% downside and likely assumes continued cap-rate pressure, weak life science demand, and margin compression that erodes dividend coverage. Institutional ratings show a clear downgrade pattern: Barclays moved from Overweight to Equal Weight on July 7, 2026, and Morgan Stanley cut from Overweight to Equal Weight on June 11, 2026, while Wells Fargo, UBS, and JP Morgan have maintained Neutral stances. The absence of recent upgrades, combined with the wide target spread and the stock's recent underperformance versus SPY, suggests analyst conviction is weakening even as the headline consensus remains Buy, a divergence that argues for caution until either leasing fundamentals inflect or the stock reclaims its 52-week high.
Bulls vs Bears: DOC Investment Factors
The bear case currently has stronger evidence due to extreme GAAP valuation, recent relative underperformance, and a clear pattern of analyst downgrades, though the bull case rests on a compelling 7.59% dividend yield and deep asset-value discount. The single most important tension is whether life science leasing and medical office occupancy can inflect enough to justify the market's modest optimism embedded in the 1.49x price-to-book, or whether structural demand concerns will keep the stock range-bound. With a beta near 1.0 and a 4.75 short ratio, sentiment could swing sharply in either direction. The 13.6% analyst upside is moderate and not overwhelming for a mature REIT, suggesting the risk/reward is balanced but tilted toward income-focused investors. Until the stock reclaims its 52-week high of $22.95 or leasing fundamentals accelerate, the bear case of range-bound performance and multiple compression remains the path of least resistance.
Bullish
- Deep value on book and sales: Price-to-book of 1.49x sits well below the 2.03x seen in Q4 2022 and the 2.0x-2.9x range of 2021-2022, while price-to-sales of 3.97x is a fraction of the 25.72x historical peak. This places DOC near the bottom of its own valuation band, offering asset-backed downside protection.
- 7.59% dividend yield with coverage: The dividend yield of 7.59% is far above the ~1.86% implied by recent historical ratio data and typical REIT sector yields. Q1 2026 free cash flow of $236.93 million covered $211.99 million of dividends, a 1.12x coverage ratio that supports the payout despite an 11.90% GAAP payout ratio.
- Improving operating leverage: Q1 2026 EBITDA of $576.94 million rose from $422.50 million in Q4 2025 and $395.53 million in Q1 2025, lifting the EBITDA margin to 76.6%. Operating margin also improved to 15.54% from 19.22% in Q1 2025, though the trend is not linear.
- Analyst consensus upside: With 19 analysts covering the stock, the consensus recommendation is Buy (mean 2.41) and the average target price of $23.05 implies 13.6% upside from $20.30. The high target of $29.00 implies 43% upside if life science leasing normalizes.
Bearish
- Extreme PE with no earnings inflection: Trailing PE of 160.80x and forward PE of 145.00x reflect near-zero GAAP earnings, and the narrow gap signals analysts do not expect a dramatic earnings recovery. Trailing net margin is just 2.53% and ROE is 0.95%, leaving little cushion if occupancy or rents soften.
- Recent momentum and relative weakness: The stock is down 1.74% over the past month and 1.89% over three months, underperforming SPY by 0.68 and 4.93 percentage points respectively. This divergence from the 19.55% six-month gain suggests the spring rally has given way to consolidation.
- Analyst downgrades and wide target spread: Barclays downgraded DOC from Overweight to Equal Weight on July 7, 2026, and Morgan Stanley cut from Overweight to Equal Weight on June 11, 2026. The target range spans $17.00 to $29.00, a $12.00 spread equal to 59% of the current price, signaling weak conviction.
- Leverage and external capital reliance: Debt-to-equity of 1.39 and a debt ratio of 0.496 indicate meaningful leverage, while Q1 2026 acquisitions of $427.85 million and debt repayment of $560.01 million were funded partly by $759.20 million of other financing activities. The cash flow-to-debt ratio of just 0.024 highlights limited internal debt-service capacity.
DOC Technical Analysis
Healthpeak is in a broad recovery phase rather than a sustained uptrend, with the shares up 11.91% over the past year but still trading at roughly 88.5% of the 52-week range (current price $20.30 versus a 52-week low of $15.70 and high of $22.95). That positioning near the upper end of the range but below the high signals the stock has recovered most of its prior drawdown without yet confirming a breakout to new highs, and the 25.31% year-to-date gain shows the recovery has been front-loaded into 2026. The stock's 18.53% maximum drawdown over the period underscores that this recovery has not been linear, and the fact that price sits about 11.5% below the 52-week high means momentum buyers still lack a clean breakout trigger. Recent momentum has clearly decelerated: the shares are down 1.74% over the past month and 1.89% over the past three months, a sharp divergence from the 19.55% six-month gain and the 11.91% one-year advance. This divergence suggests the spring rally that carried the stock from roughly $16 in early May to above $22 in late July has given way to a consolidation phase, with the stock fading from its late-July peak of $22.82 to the current $20.30. Relative strength confirms the softening, with the stock underperforming SPY by 0.68 percentage points over one month and 4.93 points over three months, even as it outperformed by 4.15 points over six months and 13.23 points year-to-date, indicating the recent weakness is a give-back of earlier leadership rather than a new downtrend. Key technical levels are well defined: support sits at the 52-week low of $15.70, with intermediate support around the $20 psychological level and the August lows near $20.44, while resistance is anchored at the 52-week high of $22.95 and the July peak of $22.82. A decisive break above $22.95 would confirm a new leg higher and likely draw momentum capital, whereas a breakdown below $20 would open the door to a retest of the $19.00-$19.50 zone and, in a worse scenario, the $15.70 low. With a beta of 0.989, Healthpeak moves roughly in line with the broader market, so position sizing does not require a volatility premium, but the 4.75 short ratio indicates a meaningful short base that could amplify moves in either direction if sentiment shifts.
Beta
0.99
0.99x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$16-$23
Price range past year
Annual Return
+11.9%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | -1.7% | -1.6% |
| 3m | -1.9% | +1.3% |
| 6m | +19.6% | +13.9% |
| 1y | +11.9% | +16.3% |
| ytd | +25.3% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Healthpeak's revenue trajectory is modestly positive but decelerating at the margin, with Q1 2026 revenue of $752.95 million representing 7.12% year-over-year growth versus Q1 2025 revenue of $702.89 million. The sequential trend shows revenue rising from $694.35 million in Q2 2025 to $705.87 million in Q3 2025, $719.40 million in Q4 2025, and $752.95 million in Q1 2026, a steady but low-single-digit sequential climb that implies annualized growth in the mid-single digits rather than acceleration. Segment data shows the outpatient medical building portfolio is the largest contributor at $318.22 million, followed by lab at $212.81 million and senior housing at $200.35 million, meaning the investment case is heavily levered to medical office performance and the still-recovering life science leasing market. The 7.12% growth rate is respectable for a healthcare REIT but not exceptional, and with analyst revenue estimates for the current year averaging $3.778 billion against a roughly $2.88 billion annualized run-rate from Q1, the market appears to expect continued mid-single-digit expansion rather than a step-change. Profitability is thin and volatile, with Q1 2026 net income of $193.63 million translating to a net margin of 25.72%, but the reported gross margin of -19.97% and gross profit of -$150.38 million reflect REIT accounting distortions (notably depreciation embedded in cost of revenue) rather than true operating losses. The more meaningful profitability signal is the operating margin of 15.54% and EBITDA of $576.94 million in Q1 2026, up from $422.50 million in Q4 2025 and $395.53 million in Q1 2025, showing improving operating leverage. However, the trailing net margin of just 2.53% and ROE of 0.95% highlight how little accounting profit the business retains after depreciation and interest, which is typical for capital-intensive healthcare REITs but leaves little cushion if occupancy or rents soften. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 1.39 and a debt ratio of 0.496, alongside a current ratio of 1.09 that indicates adequate but not abundant short-term liquidity. Free cash flow is solid at $1.182 billion on a trailing basis, and Q1 2026 free cash flow of $236.93 million was comfortably above the $211.99 million of dividends paid, implying a dividend coverage ratio near 1.12x that supports the 7.59% yield but leaves limited room for error. The company is actively recycling capital, with $427.85 million of acquisitions and $560.01 million of debt repayment in Q1 2026, funded partly by $759.20 million of other financing activities, which signals reliance on external capital markets to fund growth and refinance maturities. With ROA of just 1.51% and a cash flow-to-debt ratio of 0.024, the balance sheet is serviceable but not fortress-like, and the investment case depends on stable rates and continued asset-level cash flow growth.
Quarterly Revenue
$752952000.0B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
-20.0%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Because Healthpeak's trailing net income is positive but minimal, the PE ratio is the primary metric, and it is extreme: the trailing PE of 160.80x reflects near-zero trailing earnings, while the forward PE of 145.00x implies the market expects only modest earnings recovery. The gap between the trailing and forward PE is unusually narrow, signaling that analysts do not anticipate a dramatic earnings inflection, which is consistent with a REIT whose GAAP earnings are suppressed by depreciation and whose economic value is better captured by cash flow and dividend metrics. For a capital-intensive REIT, the more informative multiples are price-to-book at 1.49x, price-to-sales at 3.97x, and EV/EBITDA at 14.31x, the last of which is the cleanest measure of operating valuation. Peer comparison is constrained because the provided valuation dataset does not include explicit industry average multiples, so a precise premium or discount cannot be quantified; however, a 1.49x price-to-book and 14.31x EV/EBITDA are broadly in line with where diversified healthcare REITs typically trade, suggesting Healthpeak is not obviously expensive on asset or cash-flow bases despite the optically alarming PE. The 7.59% dividend yield is the standout valuation signal, sitting well above the roughly 1.86% yield implied by the most recent historical ratio data and far above typical REIT sector yields, which either reflects a genuine income opportunity or the market's skepticism about the sustainability of the payout given the 11.90% payout ratio on GAAP earnings. Historically, Healthpeak's valuation has compressed dramatically: the PE ratio has fallen from 626.75x in Q4 2022 and 804.37x in Q4 2024 to 160.80x currently, while price-to-book has declined from 2.03x in Q4 2022 to 1.49x today and price-to-sales from 25.72x to 3.97x. This places the stock near the bottom of its own historical valuation band on book and sales metrics, which could signal a value opportunity if fundamentals stabilize, but the persistent earnings weakness and the fact that price-to-book troughed at 1.25x in Q1 2024 suggest the market has repeatedly refused to pay up for these assets. The current 1.49x price-to-book is above that 1.25x trough but well below the 2.0x-2.9x range seen in 2021-2022, implying the market is pricing in modest optimism relative to the darkest point but remains far from the growth expectations embedded in prior cycles.
PE
160.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are anchored in Healthpeak's thin GAAP profitability and meaningful leverage. Trailing net margin is just 2.53% and ROE is 0.95%, leaving minimal buffer if occupancy or rents decline, while the debt-to-equity ratio of 1.39 and debt ratio of 0.496 indicate a balance sheet that relies on external capital markets. The cash flow-to-debt ratio of 0.024 is low, and Q1 2026 financing activities of $759.20 million highlight dependence on refinancing. Dividend coverage of 1.12x on free cash flow is adequate but leaves little room for error if operating cash flow weakens. Revenue concentration in outpatient medical ($318.22 million) and lab ($212.81 million) segments means any softening in these two pillars would disproportionately impact results.
Market and competitive risks stem from DOC's premium GAAP valuation and sector-specific headwinds. The trailing PE of 160.80x and forward PE of 145.00x are optically extreme, and any earnings miss could trigger multiple compression. With a beta of 0.989, the stock is highly correlated to the broader market, so a macro-driven selloff would likely drag DOC down in line. The recent downgrades by Barclays and Morgan Stanley to Equal Weight reflect growing skepticism about life science demand and cap-rate pressure. The 4.75 short ratio adds volatility risk, as short sellers could accelerate a downturn if leasing data disappoints. Additionally, the wide analyst target spread of $17.00 to $29.00 signals disagreement that could lead to sharp repricing on new information.
In a worst-case scenario, a combination of rising interest rates, weak life science leasing, and declining medical office occupancy would compress cap rates and erode dividend coverage. This could push the stock toward its 52-week low of $15.70, representing a 22.7% decline from the current price of $20.30. The analyst low target of $17.00 implies a 16.3% downside, but a more severe outcome could see the stock retest the $15.70 low if the dividend is cut or guidance is slashed. Historical maximum drawdown of 18.53% over the past year shows the stock is capable of sharp declines. In this adverse scenario, an investor could lose 16% to 23% from current levels, with the downside amplified if the 7.59% dividend yield is reduced.
FAQ
The most severe risk is a dividend cut if free cash flow coverage falls below 1.0x, as the 7.59% yield is a primary support for the stock price. Financial risk is elevated by a debt-to-equity ratio of 1.39 and a cash flow-to-debt ratio of just 0.024, indicating limited internal debt-service capacity. Competitive and structural risks include weak life science leasing and medical office occupancy, which together represent the majority of revenue and could erode same-store NOI. Macro risk is significant given the beta of 0.989, meaning DOC is highly correlated to the broader market, and rising interest rates could compress cap rates and REIT multiples. Company-specific risk includes the 4.75 short ratio, which could amplify downside if sentiment deteriorates, and the wide analyst target range of $17.00 to $29.00, signaling disagreement.
The 12-month forecast has three scenarios: a bull case with 25% probability targeting $26.00-$29.00, a base case with 55% probability targeting $21.00-$24.00, and a bear case with 20% probability targeting $15.70-$17.00. The base case is most likely, assuming revenue growth of 5-7% year over year, stable EBITDA margins above 70%, and dividend coverage above 1.1x. The bull case requires life science leasing normalization and rate cuts, while the bear case assumes weak leasing, rising rates, and a dividend cut. The analyst average target of $23.05 aligns with the base case, and the current price of $20.30 is near the lower end of the base-case range. Key catalysts include Q3 2026 earnings and any Fed rate decisions.
DOC appears undervalued on asset and sales metrics, with price-to-book at 1.49x versus 2.03x in Q4 2022 and price-to-sales at 3.97x versus a historical peak of 25.72x. However, the trailing PE of 160.80x and forward PE of 145.00x are extreme, reflecting near-zero GAAP earnings, and the EV/EBITDA of 14.31x is broadly in line with diversified healthcare REITs. The 7.59% dividend yield is well above the ~1.86% implied by recent historical ratio data, suggesting the market is pricing in skepticism about payout sustainability. Without explicit industry average multiples, a precise peer comparison is not possible, but the stock is not obviously expensive on cash-flow bases. The market appears to expect modest earnings recovery and stable leasing, with limited multiple expansion.
DOC offers a 7.59% dividend yield with 1.12x free cash flow coverage, which is attractive for income investors, and trades at 1.49x price-to-book, below its historical average. However, the trailing PE of 160.80x and forward PE of 145.00x reflect minimal GAAP earnings, and the stock has underperformed SPY by 4.93 percentage points over three months. The analyst consensus is Buy with a $23.05 average target, implying 13.6% upside, but recent downgrades by Barclays and Morgan Stanley to Equal Weight suggest caution. The biggest downside risk is a retest of the 52-week low of $15.70, representing 22.7% downside. It is a good buy primarily for income-focused investors with a long horizon who can tolerate near-term volatility and potential dividend risk.
DOC is better suited for long-term investment, given its 7.59% dividend yield, 1.49x price-to-book, and stable cash flows from a diversified healthcare real estate portfolio. The beta of 0.989 indicates market-like volatility, and the 4.75 short ratio suggests near-term trading could be choppy, making it less ideal for short-term speculation. The dividend coverage of 1.12x on free cash flow supports a minimum holding period of at least 2-3 years to capture yield and potential multiple expansion. However, the recent downgrades and weak GAAP earnings mean earnings visibility is low, so investors should monitor quarterly leasing data. A suggested minimum holding period is 3 years to allow for life science leasing recovery and cap-rate stabilization.